Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S. Amoury M, et al. Among authors: nachreiner t. Int J Cancer. 2016 Aug 15;139(4):916-27. doi: 10.1002/ijc.30119. Epub 2016 Apr 15. Int J Cancer. 2016. PMID: 27037627 Free article.
Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M, Kolberg K, Pham AT, Hristodorov D, Mladenov R, Di Fiore S, Helfrich W, Kiessling F, Fischer R, Pardo A, Thepen T, Hussain AF, Nachreiner T, Barth S. Amoury M, et al. Among authors: nachreiner t. Cancer Lett. 2016 Mar 28;372(2):201-9. doi: 10.1016/j.canlet.2016.01.027. Epub 2016 Jan 21. Cancer Lett. 2016. PMID: 26806809
SNAP-tag based agents for preclinical in vitro imaging in malignant diseases.
Amoury M, Blume T, Brehm H, Niesen J, Tenhaef N, Barth S, Gattenlöhner S, Helfrich W, Fitting J, Nachreiner T, Pardo A. Amoury M, et al. Among authors: nachreiner t. Curr Pharm Des. 2013;19(30):5429-36. doi: 10.2174/13816128113199990405. Curr Pharm Des. 2013. PMID: 23431985
14 results